オプションチェーンは、Polar Powerの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Polar Powerの市場センチメントを評価します。.

Polar Power (NASDAQ:POLA) 株価情報, オプションチェーン

Polar Power

Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications primarily in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, Back-up DC generators, hybrid power systems, Li-Ion battery systems, and Marine DC generators. The Companie's geographical presence is in the United States, Canada, Mexico, South Pacific Islands, Japan, Europe and Middle East and Other Asia Pacific countries.

Polar Power Inc

POLAR CAP GLOBAL FNCL TR by POLAR CAP GLOBAL FINANCIALS TR PLC

POLAR CAPITAL TECH TR NEW by Polar Capital Technology Trust Plc.

POLAR CAPITAL TECH TR PLC by Polar Capital Technology Trust Plc.

POLAR PETROLEUM CORP by Polar Petroleum Corp.

POLA ORBIS HOLDINGS INC by Pola Orbis Holdings Inc

Pola Orbis Holdings Inc

POLAR CAPITAL HOLDING ORD by Polar Capital Holdings PLC

Polar Capital Holdings PLC

PolarX Ltd

POLAREAN IMAGING LTD by Polarean Imaging Ltd.

Polarean Imaging PLC

POLARIS HLDGS CO LTD by POLARIS HLDGS CO LTD

Polaris Holdings Co Ltd

Polaris Inc

POLARIS INTL HOLDINGS INC by Polaris International Holdings, Inc.

Polaris International Holdings Inc

Polaris Northstar Capital Corp

POLARIS NORTHSTAR CAP CRP by POLARIS NORTHSTAR CAP CORP.

POLARIS RENEWABLE ENERGY by POLARIS RENEWABLE ENERGY INC.

Polaris Renewable Energy Inc

PolarityTE Inc

The Company reported the following results on a preliminary and unaudited basis2:
<ul>
<li>Net sales for the fourth quarter increased 5.0% to $402.0 million</li>
<li>Constant currency net sales3 for the fourth quarter increased 6.0% to $405.9 million, with the United States ("U.S.") increasing 10.5% and Canada decreasing 0.2%</li>
<li>Comparable store sales for the fourth quarter increased 1.6%, with the U.S. increasing 4.7% and Canada decreasing 2.5%</li>
<li>Net sales for fiscal 2024 increased 2.5% to $1.54 billion</li>
<li>Constant currency net sales3 for fiscal 2024 increased 3.1% to $1.55 billion, with the U.S. increasing 6.7% and Canada decreasing 1.6%</li>
<li>Comparable store sales for fiscal 2024 decreased 0.1%, with the U.S. increasing 2.7% and Canada decreasing 4.0%</li>
</ul>
Based on the preliminary fourth quarter and fiscal 2024 net sales results outlined above, the Company reaffirms its previously provided fiscal 2024 Adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA")1 outlook of approximately $290 million to $300 million.

News

Guidance

Company Reports Q4 Net Sales Up 5% To $402M; U.S. Sales Rise 10.5%, Canada Falls 0.2%; Fiscal 2024 Sales Up 2.5% To $1.54B; Reaffirms EBITDA Outlook Of $290M-$300M

HC Wainwright &amp; Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $30 to $35.

Price Target

Analyst Ratings

CPRX

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

CASH

Heritage Distilling Board Approves Bitcoin Treasury Policy

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini –
-- Data from Phase 2 VINCENT trial expected by 2H25, which explores effect of obicetrapib alone and in combination with a PCSK9i on Lp(a) –
-- Focus on commercial readiness with manufacturing capacity establishment and inventory build-out --
-- Year end, unaudited, cash balance of $835 million following oversubscribed public offering in December 2024 --
NAARDEN, The Netherlands and MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today provided an update on the obicetrapib clinical development program and outlined its strategic priorities for 2025.
NewAmsterdam is developing obicetrapib, an oral, low-dose, once-daily, and highly selective cholesteryl ester transfer protein ("CETP") inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.&nbsp;The Company's global, pivotal Phase 3 clinical development program consists of four trials in over 12,250 patients.

Biotech

General

NAMS

NewAmsterdam Pharma Outlines 2025 Strategy With Obicetrapib Focus; Expects EMA Filing In H2 2025, Unveils $835M Year-End Cash. Highlights: BROADWAY 33% LDL-C Reduction, TANDEM 49% Reduction, BROOKLYN 36% Reduction; PREVAIL Trial Ongoing. VINCENT & REMBRANDT Trials To Conclude In 2025, 2027.

INSM

Insmed Provides Outlook Ahead Of J.P. Morgan Healthcare Conference; Sees 2025 Global ARIKAYCE Revenues $405M-$425M

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range
Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19%
Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023
BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced preliminary results for the fourth quarter and full year 2024, including fourth quarter 2024 net FUROSCIX revenue and unaudited cash and cash equivalents.

Earnings

SCPH

scPharmaceuticals Reports Preliminary Q4 Revenue Of $12M-$12.3M; FY24 Revenue Expected To Be $36.2M-$36.5M

HURC

Hurco Cos Q4 EPS $(0.23) Down From $0.36 YoY, Sales And Service Fees $53.7M Down From $66.11M YoY

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">89.2000</td>
<td align="right">1.17</td>
<td align="right">1.32</td>
<td>33.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.3900</td>
<td align="right">0.38</td>
<td align="right">0.49</td>
<td>13.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">223.3000</td>
<td align="right">0.29</td>
<td align="right">0.13</td>
<td>603</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">140.5199</td>
<td align="right">0.09</td>
<td align="right">0.06</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">232.4200</td>
<td align="right">-1.460</td>
<td align="right">-0.63</td>
<td>23.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.2736</td>
<td align="right">-0.216</td>
<td align="right">-0.45</td>
<td>91.7K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 10, 2025

Rosenblatt analyst Barton Crockett maintains Liberty Formula One Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Buy and raises the price target from $93 to $102.

FWONK

Rosenblatt Maintains Buy on Liberty Formula One Gr, Raises Price Target to $102

Genius Group Adds $5M To Bitcoin Treasury

ARCT

Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial

Current Co-Chairman of the Board will now also serve as Chief Executive Officer
Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation&#x2122; (nano-PFA or nsPFA&#x2122;) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.

Management

PLSE

Pulse Biosciences Appoints Paul LaViolette As Chief Executive Officer

TYRA

Tyra Biosciences Receives IND Clearance From The FDA To Proceed With A Phase 2 Study Of TYRA-300 In Non-Muscle Invasive Bladder Cancer

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $11 price target.

Reiteration

KMDA

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

Contracts

Nano Labs Subsidiary Nano Bit, BitFi Enter Strategic Partnership; Nano Labs Agrees To Adopt Bitcoin As A Long-Term Strategic Reserve Asset, With Nano Bit Responsible For The Management And Operation Of These Assets

RVTY

Revvity Receives FDA Clearance For EUROIMMUN's Free Testosterone Test

TLSA

Tiziana Life Sciences Announced Findings On Benefits Of Its Nasal Anti-CD3 Monoclonal Antibody In Sustaining Tissue Homeostasis And Mitigating The Side Effects Associated With GLP-1 Agonists Discontinuation

<ul>
<li>Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025</li>
<li>Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified</li>
<li>Extending the cash runway to the start of 2027 by reducing costs, including an approximate 65% reduction in workforce and expected closure of the U.K. site</li>
<li>Future operations will be focused at the U.S. site in Germantown, Maryland</li>
</ul>
OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) ("Barinthus Bio," or the "Company"), today provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.

BRNS

Barinthus Bio Restructures, Prioritizes VTP-1000 For Celiac Disease With Phase 1 Data In Mid-2025, Pauses VTP-300 For Hepatitis B Pending Partner; Cuts 65% Workforce, Closes U.K. Site To Extend Cash To 2027 With $112M Reserves; Focuses U.S. Operations In Germantown

Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped over 40% in premarket after it announced a breakthrough in its True All-Solid-State <a href="https://www.benzinga.com/topic/batterie">Battery</a> (ASSB) technology. Technical analysis shows strong support for the stock performance.
What Happened: Unlike conventional batteries, Microvast&#8217;s ASSB eliminates liquid electrolytes, enabling high-voltage operation and simplifying system architecture.
&#8220;Our solid-state battery innovation represents a significant leap forward in addressing real-world safety and efficiency challenges,&#8221; stated CEO Yang Wu.
The press release lists the new battery&#8217;s key features, which include enhanced safety and efficiency along with bipolar stacking architecture, which helps achieve high voltages unattainable by liquid-based batteries. The proprietary all-solid electrolyte separator in the battery ensures conductivity and structural stability.
See Also:<a href="https://www.benzinga.com/25/01/42908280/intel-aims-for-cpu-market-share-growth-ai-breakthroughs-citi-reiterates-neutral-as-new-ceo-appointment-expected-in-coming-months"> Intel Stock Has Fallen Over 58% In 1 Year, But Citi Maintains &#8216;Neutral&#8217; Rating On Expected Replacement Of Pat Gelsinger In A &#8216;Couple Of Months&#8217; </a>
Why It Matters: Microvast&#8217;s ASSB technology is poised to transform various sectors according to the company. This technology will be helpful in data centers, electric vehicles, and advanced robotics, as it offers customized solutions with high energy density and improved safety.
Microvast was up 44.39% at $2.7 in premarket during the publication of this article. It ended 10.95% lower in Wednesday&#8217;s session. The shares have risen by a staggering 345.24% over the last six months and 61.21% over the last year. Nasdaq Composite underperformed the stock as it rose 4.46% in the last six months and 30.1% over the last year.
Technical analysis of daily moving averages with the help of <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> shows strong support for the stock in both the near and long term.
Mirovast&#8217;s shares in premarket trade were above its eight-day simple moving average of $2.29 and its 20-day average of $1.87 apiece, showing strong support in the near term.
The 50 and 200-day simple moving averages were also below the share price at $1.13 and $0.57, respectively, suggesting a bullish uptrend.
On the other hand, the relative strength index of 62.97 suggested that the stock could be moderately overbought but still in the neutral zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1024x576.png" alt="" class="wp-image-727887" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42893264/charlie-mungers-top-pick-costco-reports-strong-december-sales-analysts-expect-a-7-jump-in-january">Charlie Munger&#8217;s Top Pick Costco Reports Strong December Sales: Analysts Expect A 7% Jump In January</a> 
According to <a href="https://www.benzinga.com/quote/MVST/analyst-ratings">Benzinga</a>, MVST has a consensus price target of $4.4 per share based on the ratings of five analysts. The highest price target out of all the analysts tracked by Benzinga is $8 apiece issued by Cantor Fitzgerald as of Dec. 18. The lowest target price is $3 per share issued by HC Wainwright &amp; Co. on Nov. 18.
The average recent price target between HC Wainwright &amp; Co. and Janney Montgomery Scott implies a 24.22% upside for MVST.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/MVST/analyst-ratings"><img loading="lazy" decoding="async" width="945" height="355" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR.png" alt="" class="wp-image-727883" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR.png 945w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR-768x289.png 768w" sizes="(max-width: 945px) 100vw, 945px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42906089/california-wildfires-ignite-concerns-for-insurance-stocks-here-are-some-insurance-etfs-which-could-be-impacted">California Wildfires Ignite Concerns For Insurance Stocks: Here Are Some Insurance ETFs Which Could Be Impacted </a></li>
</ul>
Image courtesy of Microvast

Analyst Color

Equities

Market Summary

Technicals

Trading Ideas

MVST

Microvast's Breakthrough In All-Solid State Battery Tech Propels Shares To Over 40% In Premarket: Here's What Technical Analysis Says

TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) reported quarterly earnings of $3.09 per share which beat the analyst consensus estimate of $3.05 by 1.31 percent. The company reported quarterly sales of $15.845 billion which beat the analyst consensus estimate of $15.220 billion by 4.11 percent. This is a 9.98 percent increase over sales of $14.407 billion the same period last year.

Earnings Beats

TD Synnex Q4 2024 Adj. EPS $3.09 Beats $3.05 Estimate, Sales $15.845B Beat $15.220B Estimate

Polar Power expects net sales to jump in Q3

Here's the major earnings before the open tomorrow

An update from Polar Power ( ($POLA) ) is now available. Polar Power, Inc. reported strong financial results for Q3 2024, with net sales of $4.9 mi...

Polar Power Reports Strong Q3 2024 Financial Results

Polar Power GAAP EPS of $0.00, revenue of $4.91M

Polar Power (POLA) announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 7 pre-s...

Polar Power announces 1-for-7 reverse stock split

These are the upcoming stock splits for the week of November 18 to November 22, based on&nbsp;TipRanks' Stock Splits Calendar. A&nbsp;stock split&n...

Upcoming Stock Splits This Week (November 18 to November 22) – Stay Invested

19:50 EST Polar Power (POLA) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Polar Power trading halted, news pending

Polar Power (POLA) regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market. The Company has received notifi...

Polar Power regains compliance with Nasdaq listing rules

Polar Power receives letter from Nasdaq acknowledging listing compliance

Oil opens new year with strong gains on optimism over economic rebound in China

ABAT

AFMD

AMRC

ARRY

AZUL

BILI

BLUE

BOIL

BTAI

CASI

CLMT

CRIS

CVSI

DRIP

DTEGY

EONGY

FTCI

GASS

GEVO

GPRK

GUSH

IMPP

ITRM

JFBR

KEYUF

KNOP

KNTNF

KOLD

LEEEF

LTBR

LUNR

MKGAF

MMLP

MNTK

NEXA

NICE

NLCP

NOVA

NRGV

NTES

OCUL

ONEW

PAVM

PDSB

POLA

PPIH

PVCT

QBTS

SACH

SDST

SIEGY

SPCB

SUUN

USOI

VEON

VISL

WAVE

WHLR

WKHS

XNET

Press Releases

Polar Power Reports Full Year and Fourth Quarter 2023 Financial Results

Polar Power Reports First Quarter 2024 Financial Results

Polar Power Announces Preliminary Second Quarter 2024 Corporate and Financial Update

Polar Power Appoints Michael Field as Independent Director and Compensation Committee Chair

Polar Power Reports Second Quarter 2024 Financial Results

Penny Stocks

Polar Power Completes Installation of UNHCR Nigeria Contract

Polar Power Announces Preliminary 2024 Third Quarter Financial Results: Expected Net Sales of $4.7 - $5.2 Million and Gross Margin of 26%-32%

Polar Power Reports Third Quarter 2024 Financial Results

Polar Power Announces Reverse Stock Split

Polar Power Announces Receipt of Letter from Nasdaq Acknowledging Listing Compliance

Comments

Polar Power

Polar Power (POLA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル